Surgery Plus Chemotherapy Versus Surgery Alone for Limited-Stage Small-Cell Lung Cancer: A Population-Based Survival Outcome Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jun 3

PMID 34079765

Citations 5

Authors

Pingting Ye

Zhuolin Guo

Yanfei Zhang

Chunyan Dong

Ming Li

Affiliations

Soon will be listed here.

Abstract

Introduction: For patients with limited-stage small-cell lung cancer (LS-SCLC), effective treatment methods still remain a clinical challenge. The aim of this study is to evaluate the survival outcome of surgery plus chemotherapy surgery alone in patients with LS-SCLC.

Methods: LS-SCLC patients selected from the Surveillance, Epidemiology and End Results (SEER) database diagnosed between January 1, 2004, and December 31, 2015. Comparison of overall survival (OS) and cancer-specific survival (CSS) between two groups performed propensity score matching (PSM), inverse probability of treatment weight (IPTW), and overlap weighting analysis.

Results: Of the 477 LS-SCLC patients identified from the SEER database between 2004 and 2015, 262 (54.9%) received surgery-plus-chemotherapy treatment and the others received surgery-alone treatment. Univariate and multivariate analyses showed that treatment option (< 0.001), tumor location (= 0.02) and AJCC stage (< 0.001) were independent prognostic predictors of OS in LS-SCLC patients. Median OS was 35 months in surgery-plus-chemotherapy group 23 months in surgery-alone group. Survival analysis showed that surgery plus chemotherapy offered significantly improved OS as compared with surgery-alone treatment before and after IPTW, PSM and overlap weighting method (all < 0.05). According to AJCC stage stratification, OS of the unmatched patients with stage I (= 0.049) and II (= 0.001) SCLC who received surgery-plus-chemotherapy treatment was significantly better than that of surgery-alone patients.

Conclusions: This cohort study showed that surgery plus chemotherapy was associated with longer survival time than surgery alone in LS-SCLC patients, especially in those with stage I and II SCLC. Further prospective studies are required to confirm our conclusions.

Citing Articles

Effect of surgery on survival of patients with small-cell lung cancer undiagnosed before resection.

Caput B, Peretti L, Lacomme S, Tiotiu A Ann Thorac Med. 2024; 19(4):258-265.

PMID: 39544347 PMC: 11559700. DOI: 10.4103/atm.atm_42_24.

The cross-regional settlement methods in hospitals and the treatment-seeking behavior of patients with malignant tumors in China: an evolutionary game model.

Zhao X, Li L, Zhang D Front Public Health. 2024; 12:1427164.

PMID: 39086813 PMC: 11289844. DOI: 10.3389/fpubh.2024.1427164.

CD3, CD8, IFN-γ, tumor and stroma inflammatory cells as prognostic indicators for surgically resected SCLC: evidences from a 10-year retrospective study and immunohistochemical analysis.

Fu M, Feng C, Wang J, Guo C, Wang Y, Gao R Clin Exp Med. 2024; 24(1):99.

PMID: 38748269 PMC: 11096253. DOI: 10.1007/s10238-024-01329-9.

Efficacy evaluation of surgery combined with chemotherapy for stage IIIA small cell lung cancer patients: a retrospective analysis.

Bian D, Jiang S, Xiong Y, Qi M, Wu J, Addeo A Transl Lung Cancer Res. 2022; 11(8):1631-1642.

PMID: 36090643 PMC: 9459616. DOI: 10.21037/tlcr-22-545.

Editorial: Surgical Selection of Sublobar Resection and Scope of Lymph Node Dissection for Early-Stage Lung Cancer.

Sun J, Zhu C, Shen J Front Surg. 2022; 9:915220.

PMID: 35647018 PMC: 9130624. DOI: 10.3389/fsurg.2022.915220.

References

Yang C, Chan D, Speicher P, Gulack B, Wang X, Hartwig M . Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. J Clin Oncol. 2016; 34(10):1057-64. PMC: 4933132. DOI: 10.1200/JCO.2015.63.8171. View

Ning Y, Bao M, Yan X, Xie D, Jiang G . Surgery for advanced non-small cell lung cancer patient after epidermal growth factor receptor tyrosine kinase inhibitor neoadjuvant therapy. Ann Transl Med. 2018; 6(20):407. PMC: 6230859. DOI: 10.21037/atm.2018.10.06. View

Shepherd F, Evans W, Feld R, Young V, Patterson G, Ginsberg R . Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. J Clin Oncol. 1988; 6(5):832-8. DOI: 10.1200/JCO.1988.6.5.832. View

SHIELDS T, HIGGINS Jr G, Matthews M, KEEHN R . Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg. 1982; 84(4):481-8. View

Lally B, Urbanic J, Blackstock A, Miller A, Perry M . Small cell lung cancer: have we made any progress over the last 25 years?. Oncologist. 2007; 12(9):1096-104. DOI: 10.1634/theoncologist.12-9-1096. View

Hara N, Ohta M, Ichinose Y, Motohiro A, Kuda T, Asoh H . Influence of surgical resection before and after chemotherapy on survival in small cell lung cancer. J Surg Oncol. 1991; 47(1):53-61. DOI: 10.1002/jso.2930470112. View

Shepherd F, Ginsberg R, Feld R, Evans W, Johansen E . Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. J Thorac Cardiovasc Surg. 1991; 101(3):385-93. View

Che K, Shen H, Qu X, Pang Z, Jiang Y, Liu S . Survival Outcomes for Patients with Surgical and Non-Surgical Treatments in Stages I-III Small-Cell Lung Cancer. J Cancer. 2018; 9(8):1421-1429. PMC: 5929087. DOI: 10.7150/jca.23583. View

Cronin K, Ries L, Edwards B . The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer. 2014; 120 Suppl 23:3755-7. DOI: 10.1002/cncr.29049. View

10.

Duma N, Santana-Davila R, Molina J . Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. Mayo Clin Proc. 2019; 94(8):1623-1640. DOI: 10.1016/j.mayocp.2019.01.013. View

11.

Puma F, Urbani M, Santoprete S, Ricci F, Sanguinetti A, Vinci D . [The role of surgery in the treatment of small cell lung cancer]. Minerva Endocrinol. 2002; 26(4):247-53. View

12.

Siegel R, Ma J, Zou Z, Jemal A . Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. DOI: 10.3322/caac.21208. View

13.

Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A . Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017; 18(8):1116-1125. PMC: 5555437. DOI: 10.1016/S1470-2045(17)30318-2. View

14.

Gronberg B, Killingberg K, Flotten O, Brustugun O, Hornslien K, Madebo T . High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. 2021; 22(3):321-331. DOI: 10.1016/S1470-2045(20)30742-7. View

15.

Xu J, Yang H, Fu X, Jin B, Lou Y, Zhang Y . Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer. J Thorac Oncol. 2016; 12(2):347-353. DOI: 10.1016/j.jtho.2016.09.133. View

16.

Kalemkerian G, Akerley W, Bogner P, Borghaei H, Chow L, Downey R . Small cell lung cancer. J Natl Compr Canc Netw. 2013; 11(1):78-98. PMC: 3715060. DOI: 10.6004/jnccn.2013.0011. View

17.

Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K . Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res. 2019; 11:943-953. PMC: 6345192. DOI: 10.2147/CMAR.S187317. View

18.

Shibayama T, Hiyama J, Ueoka H, Tabata M, Segawa Y, Gemba K . [Induction chemotherapy followed by adjuvant surgery (IC-AS) in patients with stage I-II small cell lung cancer (SCLC)]. Gan To Kagaku Ryoho. 1995; 22(13):1953-8. View

19.

Takei H, Kondo H, Miyaoka E, Asamura H, Yoshino I, Date H . Surgery for small cell lung cancer: a retrospective analysis of 243 patients from Japanese Lung Cancer Registry in 2004. J Thorac Oncol. 2014; 9(8):1140-5. DOI: 10.1097/JTO.0000000000000226. View

20.

LEWINSKI T, ZULAWSKI M, Turski C, Pietraszek A . Small cell lung cancer I--III A: cytoreductive chemotherapy followed by resection with continuation of chemotherapy. Eur J Cardiothorac Surg. 2001; 20(2):391-8. DOI: 10.1016/s1010-7940(01)00787-4. View